FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer By Ogkologos - January 29, 2026 338 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Patients Treated With Chemotherapy and B Cell–Targeting Agents Show Impaired Serological... October 1, 2021 Persistent Poverty Linked to Increased Risk of Dying from Cancer November 19, 2020 An Oncology Hospital at Home Model of Acute Care Shows Promise May 21, 2021 Assisted Reproduction Treatments are Safe in Young Breast Cancer Survivors with... May 15, 2024 Load more HOT NEWS Breaking down changes in NHS cancer waiting times in England FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Science Surgery: ‘Can cancers develop in the heart?’ Tattoo Artist Offers Free Nipple Tattoos To Breast Cancer Patients That...
